Cargando…

Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom

Soft tissue sarcomas are a rare type of cancer generally treated with palliative chemotherapy when in the advanced stage. There is a lack of published health utility data for locally advanced “inoperable”/metastatic disease (ASTS), essential for calculating the cost-effectiveness of current and futu...

Descripción completa

Detalles Bibliográficos
Autores principales: Guest, Julian F., Sladkevicius, Erikas, Gough, Nicholas, Linch, Mark, Grimer, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613051/
https://www.ncbi.nlm.nih.gov/pubmed/23576896
http://dx.doi.org/10.1155/2013/863056
_version_ 1782264703057133568
author Guest, Julian F.
Sladkevicius, Erikas
Gough, Nicholas
Linch, Mark
Grimer, Robert
author_facet Guest, Julian F.
Sladkevicius, Erikas
Gough, Nicholas
Linch, Mark
Grimer, Robert
author_sort Guest, Julian F.
collection PubMed
description Soft tissue sarcomas are a rare type of cancer generally treated with palliative chemotherapy when in the advanced stage. There is a lack of published health utility data for locally advanced “inoperable”/metastatic disease (ASTS), essential for calculating the cost-effectiveness of current and future treatments. This study estimated time trade-off (TTO) and standard gamble (SG) preference values associated with four ASTS health states (progressive disease, stable disease, partial response, complete response) among members of the general public in the UK (n = 207). The four health states were associated with decreases in preference values from full health. Complete response was the most preferred health state (mean utility of 0.60 using TTO). The second most preferred health state was partial response followed by stable disease (mean utilities were 0.51 and 0.43, respectively, using TTO). The least preferred health state was progressive disease (mean utility of 0.30 using TTO). The utility value for each state was significantly different from one another (P < 0.001). This study demonstrated and quantified the impact that different treatment responses may have on the health-related quality of life of patients with ASTS.
format Online
Article
Text
id pubmed-3613051
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36130512013-04-10 Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom Guest, Julian F. Sladkevicius, Erikas Gough, Nicholas Linch, Mark Grimer, Robert Sarcoma Research Article Soft tissue sarcomas are a rare type of cancer generally treated with palliative chemotherapy when in the advanced stage. There is a lack of published health utility data for locally advanced “inoperable”/metastatic disease (ASTS), essential for calculating the cost-effectiveness of current and future treatments. This study estimated time trade-off (TTO) and standard gamble (SG) preference values associated with four ASTS health states (progressive disease, stable disease, partial response, complete response) among members of the general public in the UK (n = 207). The four health states were associated with decreases in preference values from full health. Complete response was the most preferred health state (mean utility of 0.60 using TTO). The second most preferred health state was partial response followed by stable disease (mean utilities were 0.51 and 0.43, respectively, using TTO). The least preferred health state was progressive disease (mean utility of 0.30 using TTO). The utility value for each state was significantly different from one another (P < 0.001). This study demonstrated and quantified the impact that different treatment responses may have on the health-related quality of life of patients with ASTS. Hindawi Publishing Corporation 2013 2013-03-17 /pmc/articles/PMC3613051/ /pubmed/23576896 http://dx.doi.org/10.1155/2013/863056 Text en Copyright © 2013 Julian F. Guest et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Guest, Julian F.
Sladkevicius, Erikas
Gough, Nicholas
Linch, Mark
Grimer, Robert
Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
title Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
title_full Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
title_fullStr Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
title_full_unstemmed Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
title_short Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
title_sort utility values for advanced soft tissue sarcoma health states from the general public in the united kingdom
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613051/
https://www.ncbi.nlm.nih.gov/pubmed/23576896
http://dx.doi.org/10.1155/2013/863056
work_keys_str_mv AT guestjulianf utilityvaluesforadvancedsofttissuesarcomahealthstatesfromthegeneralpublicintheunitedkingdom
AT sladkeviciuserikas utilityvaluesforadvancedsofttissuesarcomahealthstatesfromthegeneralpublicintheunitedkingdom
AT goughnicholas utilityvaluesforadvancedsofttissuesarcomahealthstatesfromthegeneralpublicintheunitedkingdom
AT linchmark utilityvaluesforadvancedsofttissuesarcomahealthstatesfromthegeneralpublicintheunitedkingdom
AT grimerrobert utilityvaluesforadvancedsofttissuesarcomahealthstatesfromthegeneralpublicintheunitedkingdom